Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
Cancers | Free Full-Text | Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer | British Journal of Cancer
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
A) Disease-free survival, (B) progression-free survival and (C)... | Download Scientific Diagram
Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom?
Progression-free survival and overall survival. Progression-free... | Download Scientific Diagram
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Comparison of progression-free survival (A) or overall survival (B)... | Download Scientific Diagram
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for. - ppt download
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
Progression-free survival (PFS), event-free survival (EFS), and overall... | Download Scientific Diagram
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis - Katrin M. Sjoquist, Sarah J. Lord, Michael L. Friedlander, Robert John Simes, Ian C. Marschner,
Progression-free survival (PFS) (A) and overall survival (OS) (B) based... | Download Scientific Diagram
Progression-free survival as a surrogate endpoint for overall survival | OTT
![PDF] Clinical endpoints in oncology - a primer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f33163534f9a85acc25579932597eab0cf9e71ff/7-Figure1-1.png "PDF] Clinical endpoints in oncology - a primer. | Semantic Scholar")
PDF] Clinical endpoints in oncology - a primer. | Semantic Scholar
